Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
Minimalist illustration of a data chart representing analytics in biotech.

Jul 20, 2026

MEDDDICAL Announces RWE Strategy Advisory for Biotech Clinical Development

MEDDDICAL has introduced a new Real-World Evidence (RWE) advisory service aimed at supporting biotech companies in navigating the complexities of clinical development.This advisory service is tailored for pharmaceutical and biotech teams that require enhanced data strategies, predictive analytics, and market access insights as they face shortened development timelines. It focuses on areas such as claims data strategy, synthetic patient cohort analysis, and AI-driven analytics, enabling companies
3D imaging system in a surgical room

Jul 20, 2026

AI, imaging and implants: Taiwan's medtech innovators on show

Taiwan's medtech sector is showcasing innovative solutions that leverage AI and imaging technologies to enhance surgical procedures and training.A notable advancement is a 3D imaging system designed to improve the quality of minimally invasive surgical recordings, such as those used in endoscopic and laparoscopic surgeries. This technology not only captures high-resolution footage but also facilitates more precise image annotation and recognition. An intelligent annotation system further enhance
A biopsy sample on a lab bench next to a microscope in a dimly lit laboratory.

Jul 20, 2026

Tempus to Acquire Personalis, Integrating MRD Technology Into AI Oncology Platform

Tempus has announced its acquisition of Personalis, aiming to enhance its capabilities in minimal residual disease (MRD) technology, a key area in oncology.This strategic move is seen as a significant opportunity for Tempus, potentially valued at $20 billion, as it seeks to broaden its influence across the cancer care spectrum. The integration of Personalis' advanced MRD technology into Tempus' existing multimodal data and AI platform is expected to enhance cancer monitoring and improve clinical
DGX SuperPOD in a laboratory

Jul 20, 2026

Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory

Bristol Myers Squibb (BMS) is enhancing its computational capabilities by expanding its collaboration with Nvidia through the deployment of a DGX SuperPOD featuring DGX Vera Rubin NVL72 systems. This upgrade positions BMS to possess the most advanced Nvidia infrastructure dedicated to life sciences, building on nearly three years of partnership with Nvidia.The new Vera Rubin architecture significantly boosts performance, delivering up to ten times greater efficiency per megawatt compared to prev
A minimalist illustration of a molecule and DNA strand for drug discovery.

Jul 20, 2026

BMS Deploys NVIDIA AI Infrastructure for Drug Discovery

Bristol Myers Squibb (BMS) is significantly enhancing its AI capabilities through a collaboration with NVIDIA, focusing on the deployment of advanced DGX SuperPOD systems. This initiative aims to bolster AI-driven drug discovery efforts across BMS’s research portfolio, marking a milestone as it establishes one of the most powerful and energy-efficient AI infrastructures within the life sciences sector.The integration of NVIDIA’s BioNeMo platform will allow BMS to leverage AI models for molecular
A minimalist illustration of a heart and echocardiogram waveform on a solid background.

Jul 20, 2026

Ventripoint Diagnostics' VMS+ Technology Selected for World-First AI Cardiac Monitoring Study in Breast Cancer Patients

Ventripoint Diagnostics has announced that its VMS+ technology will play a crucial role in a pioneering NHS study aimed at detecting chemotherapy-related heart damage in breast cancer patients.The study, named AIRES (Artificial Intelligence Reconstruction of Echocardiography Study), is being conducted at The Royal Wolverhampton NHS Trust and is notable for being the first of its kind to focus specifically on oncology patients undergoing chemotherapy. It will include over 500 participants and aim
A minimalist illustration of a computer chip with energy waves, symbolizing advanced AI infrastructure.

Jul 20, 2026

Bristol Myers Squibb to build the most powerful AI factory in life sciences with NVIDIA

Bristol Myers Squibb (BMS) is set to enhance its computational capabilities by deploying an NVIDIA DGX SuperPOD, establishing one of the most advanced AI infrastructures in the life sciences sector.This new infrastructure will significantly boost BMS's computational power and efficiency, allowing for up to ten times better performance per megawatt compared to previous systems. This advancement enables the company to tackle more complex AI tasks without a proportional increase in energy use, alig
A leaf and gear silhouette representing green skills and technology.

Jul 20, 2026

Telangana to Launch Green Skills and Applied AI Centre of Excellence with Microsoft

The Telangana government is set to establish a Green Skills and Applied AI Centre of Excellence in Hyderabad, aimed at equipping youth with skills in artificial intelligence and sustainable manufacturing. This initiative, developed in collaboration with Microsoft, the 1M1B Foundation, and MeitY Startup Hub, is expected to commence operations by August 2026.The Centre is part of a broader strategy to enhance Telangana's status as a key player in India's life sciences and pharmaceutical sectors. I
A vial of liquid medication on a laboratory countertop in a dimly lit setting.

Jul 20, 2026

Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer

Bristol Myers Squibb (BMS) has joined the trend of pharmaceutical companies announcing the construction of large AI supercomputers, marking a significant step in leveraging advanced computational power for drug development.In a recent announcement, BMS revealed its plans to build what it claims will be the largest AI supercomputer in the life sciences sector. This follows similar declarations from other pharma companies within the past nine months. Initially, BMS partnered with NVIDIA three year
A minimalist illustration of a brain and euro coin representing AI talent and investment.

Jul 20, 2026

No talent, no sovereignty: The blind spot in Europe’s Tech strategy

Europe faces a critical challenge in achieving its tech sovereignty, as it grapples with a paradox of investment and talent retention in the AI sector.The European Union (EU) is significantly lagging behind the US and China in AI investment, allocating only 4% of what the US spends. In 2024, the EU invested around €37.57 billion in AI, while the US and China invested €255.3 billion and €77 billion, respectively. This disparity raises concerns about Europe’s ability to cultivate a competitive AI
A heart silhouette with circuit patterns representing AI in healthcare.

Jul 20, 2026

Bitcot: San Diego Healthcare Software Development Company Driving AI-Powered Digital Health Innovation

Bitcot, a San Diego-based healthcare software development company, is expanding its offerings to enhance AI-driven digital health solutions for U.S. healthcare providers.In response to the increasing demand for AI integration in healthcare, Bitcot is broadening its services to include advanced automation and intelligent applications. This expansion aligns with the pressing need for healthcare organizations to modernize their systems, ensure interoperability, and adopt AI responsibly while safegu
A banana peel on a laboratory countertop

Jul 20, 2026

UK biotech venture investment remains buoyant in Q2

UK biotech ventures experienced a significant surge in investment during the second quarter of the year, reaching a five-year high of over £2 billion, as reported by the Bioindustry Association (BIA). This substantial funding underscores the UK's position as a leader in Europe's biotech investment landscape.Notably, the majority of this funding stemmed from Isomorphic Labs, which raised £1.6 billion in its second round of financing. However, the BIA emphasizes that this growth reflects a genuine